BackPhoenix Biotech Acquisition Overview

Phoenix Biotech Acquisition Receivables

Phoenix Biotech Acquisition's receivables is $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer trimmed avg / median

Loading

Phoenix Biotech Acquisition Receivables History

Loading

Phoenix Biotech Acquisition vs. peers: Receivables Comparison

Loading

Phoenix Biotech Acquisition Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Phoenix Biotech Acquisition (PBAX) FAQ

Phoenix Biotech Acquisition (PBAX) currently reports a receivables of $0 as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Phoenix Biotech Acquisition's receivables history and peer comparisons.

Phoenix Biotech Acquisition's receivables changed from $0 to $0 (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Phoenix Biotech Acquisition reported $0 in receivables as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Phoenix Biotech Acquisition, and consider following PBAX for alerts when major investors trade the stock.